Frequently asked questions
In 2022, the market for COMT inhibitors was estimated to be worth USD 948.5 million.
The market for COMT inhibitors is anticipated to increase at a CAGR of 8.60% from 2023 to 2030, reaching USD 1835.16 million in 2030.
Tolcapone is the most popular category of product type.
Parkinson’s disease, by indication, is the notable segment.
During the projection period, the levodopa category is anticipated to exhibit the highest CAGR.
The COMT inhibitors market was ruled by North America.
The top players include Orion Corporation, Roche, AbbVie Inc., Acadia Pharmaceuticals, Amneal Pharmaceutical, UCB, Teva Pharmaceutical, Novartis AG, Lundbeck A/S, and others.
The growing usage of COMT inhibitors as supplementary therapy for treating ADHD symptoms and research into their potential to improve focus, memory, and cognitive function are the factors propelling the growth of the COMT inhibitors market.
The challenges limiting the growth of the COMT inhibitors market are reimbursement challenges and varying insurance coverage for COMT inhibitors affected patient access, disease complexity, and drug-drug interactions.
The aspects that generate substantial prospects for the COMT inhibitors market include investigating the potential uses of currently available COMT inhibitors for other medical disorders and investigating the development of biologic COMT inhibitors for improved therapeutic benefits.